250 related articles for article (PubMed ID: 34899602)
1. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
[TBL] [Abstract][Full Text] [Related]
2. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
3. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
[TBL] [Abstract][Full Text] [Related]
4. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
5. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
6. Genotype-Phenotype Correlations and Clinical Outcomes in 155 Cases of Pheochromocytoma and Paraganglioma.
Wang H; Papachristos AJ; Gill AJ; Clifton-Bligh R; Aniss AM; Glover A; Sywak M; Sidhu SB
World J Surg; 2023 Mar; 47(3):690-698. PubMed ID: 36550325
[TBL] [Abstract][Full Text] [Related]
7. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
8. Risk of metastatic pheochromocytoma and paraganglioma in
Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
10. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
11. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
Wang LL; Wei XJ; Zhang QC; Li F
Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
Li M; Prodanov T; Meuter L; Kerstens MN; Bechmann N; Prejbisz A; Remde H; Timmers HJLM; Nölting S; Talvacchio S; Berends AMA; Fliedner S; Robledo M; Lenders JWM; Pacak K; Eisenhofer G; Pamporaki C
J Clin Endocrinol Metab; 2023 Jan; 108(2):397-404. PubMed ID: 36190922
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features of patients with metastatic pheochromocytoma/paraganglioma].
Cui YY; Zhou Y; Gao YJ; Li TY; Wang Y; Zhang WQ; Zhou T; Chen S; Tong AL
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1174-1179. PubMed ID: 38583049
[No Abstract] [Full Text] [Related]
15.
Bayley JP; Bausch B; Jansen JC; Hensen EF; van der Tuin K; Corssmit EP; Devilee P; Neumann HP
J Med Genet; 2023 Jan; 60(1):25-32. PubMed ID: 34750193
[TBL] [Abstract][Full Text] [Related]
16. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
17. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
[TBL] [Abstract][Full Text] [Related]
18. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
[TBL] [Abstract][Full Text] [Related]
19. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
20. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
